At the beginning of the Year of the Dragon, after the approval of the oral version of semaglutide at the end of January 2024, the "* medicine" sector once again ushered in major good news.
On the evening of February 19, Boji Pharmaceutical (300404SZ) announced that the company successfully signed a "first-class drug" research and development contract worth up to 100 million.
According to the announcement, Boji Pharmaceutical signed the "Technical Service (Entrustment) Contract" with Jiangsu Nuotai AoSino Biopharmaceutical Co., Ltd., with a total contract amount of 10.8 billion yuan (tax included). The contract stipulates that Nuotai Biotech entrusts Boji Pharmaceutical to provide clinical research services of "semaglutide injection".
Semaglutide injection, as a high-profile new type of drug, has broad market prospects. This large order has also injected new vitality into the strong performance of the stock prices of enterprises in the "first-class medicine" industry chain. The day after the announcement, the news was quickly transmitted to the capital market. After the opening of the market on February 20, the share price of Boji Pharmaceutical rose strongly, and on the same day, Hanyu Pharmaceutical (300199SZ), Jinkai Biosciences (301509SZ), Sirnaomics (688117SH) and so on.
Today, Boji Pharma continued to rise again. Market analysts believe that Boji Pharmaceutical is expected to seize more market share in the first-class pharmaceutical industry chain by virtue of its deep accumulation and excellent performance in the field of clinical research services.
Boji Pharma signed a contract with Nuotai Biotech 10.8 billion clinical research contracts.
On the evening of February 19, Boji Pharmaceutical issued a major contract announcement, announcing that it had signed a "Technical Service (Entrustment) Contract" with Nuotai Biotech, with a total contract amount of up to 10.8 billion yuan (tax included), becoming the first large order in the pharmaceutical industry in the Year of the Dragon.
According to the contract, Nuotai Biotech entrusted Boji Pharmaceutical to provide clinical research services for "semaglutide injection" to complete the clinical efficacy and safety study of the drug in patients with type 2 diabetes and obesity.
It is reported that Nuotai Biotech is a biopharmaceutical company focusing on the combination of independent R&D and customized R&D and production of peptide drugs and small molecule chemical drugs, and successfully landed on the Science and Technology Innovation Board in May 2021. The cooperation with Boji Pharma will help Nuotai Biotech to gain more market share in the field of diabetes**.
As the hottest "miracle drug" on the market in recent years, semaglutide injection has long been widely recognized at home and abroad. On January 26 this year, Novo Nordisk's oral semaglutide product for hypoglycemic indications was also approved for domestic marketing.
At present, there are no semaglutide-related products on the market, and only Federal Pharmaceutical (03933.)HK), Livzon Group (000513SZ) and Huadong Medicine (000963SZ) indirectly held three companies of Jiuyuan Gene have been approved for clinical trials. The cooperation between Nuotai Biotech and Boji Pharmaceutical will undoubtedly further promote the development of the domestic market.
The day after the announcement, the secondary market reacted strongly, and on February 20, Boji Pharmaceutical quickly closed the daily limit, rising by 2003%, and the stock price closed at 743 yuan shares, with a total market value of 283.8 billion yuan. Nuotai Biotech also rose by more than 10% in early trading, with a * increase of 526%。
It is reported that semaglutide injection is a new long-acting glucagon-like peptide-1 (GLP-1) analog, developed by Novo Nordisk. The drug is primarily used for glycemic control in patients with type 2 diabetes who are not glycemic on metformin and/or sulfonylureas, and to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in patients with type 2 diabetes** with cardiovascular disease.
As the main content of this contract, Boji Pharma will be responsible for examining and completing the clinical efficacy and safety study of semaglutide injection in patients with type 2 diabetes and obesity in accordance with the relevant requirements and regulations of the industry. This research will cover all stages of drug development, production and clinical application, and provide comprehensive technical support for Nuotai Biotech.
It is worth noting that in the context of the continuous fire of the concept of first-class medicine, this cooperation with Nuotai Biotech is not the first time that Boji Pharma has set foot in the field of first-class medicine. As early as September last year, Boji Pharmaceutical said on the interactive platform that its holding subsidiary, Boji Polypeptide, is mainly engaged in the commissioned research and development of pharmaceutical peptide API and beauty peptide API, and can provide API production services for first-class drugs. In addition, the company has also provided customers with technical research and development services for liraglutide APIs and injections, which has been completed.
From the perspective of the entire market, with the increasing global attention to diabetes and obesity, semaglutide injection, as a new type of first-class drug, is of great importance for clinical research. With its rich experience and professional technical team, Boji Pharma will provide high-quality clinical research services for Nuotai Biotech and promote the research and development process of semaglutide injection.
Involved in the first-class pharmaceutical track, Boji Pharma aims at the market potential of 100 billion yuan.
Against the backdrop of rising diabetes rates around the world, the demand for diabetes** has also grown significantly.
Taking Novo Nordisk, a leading company in the field of diabetes, as an example, it has achieved strong growth in performance with its star products such as GLP-1 analogue semaglutide injection. According to the third quarter report of 2023 released by Novo Nordisk, the company achieved sales revenue of 1663 in the first three quartersDKK 9.8 billion, up 29% year-on-year; Operating profit was 758DKK 0.8 billion, up 31% year-on-year; Net profit was 617DKK 2 billion, up 47% year-on-year.
Among them, GLP-1 drugs contributed 1157 to Novo NordiskDKK 7.4 billion, accounting for almost 70% of the company's total revenue. Among them, in the first three quarters of Novo Nordisk, its subcutaneous injection preparation Ozempic (for hypoglycemia) achieved revenue of 6565.3 billion Danish kroner (about 93.).US$4.9 billion); Sales of oral tablets Rybelsus (for lowering blood sugar) reached 1284 billion Danish kroner (about 18.)US$2.8 billion), a year-on-year increase of 77%; The sales performance of Wegovy, a weight-saving product, reached 2172.9 billion Danish kroner (about 30US$9.4 billion), a year-on-year increase of 481%. The above three products together contributed 1002 to Novo Nordisk in nine months2.2 billion Danish kroner (about 142.).7.1 billion US dollars, equivalent to 1043 yuan9 billion yuan).
In the Chinese market, Novo Nordisk's revenue in Q3 of China last year reached 1326.9 billion Danish kroner (about 19.9 billion.)US$2.7 billion), up 3% year-on-year. Among them, GLP-1 product revenue was 620.8 billion Danish kroner (about 90.3 billion U.S. dollars), accounting for 766% market share.
Such a large market share has also attracted a number of domestic enterprises. As a leading enterprise in the field of CRO in China, Boji Pharmaceutical has been committed to providing a full range of services for the R&D and production of drugs, medical devices and health care products for domestic and foreign pharmaceutical companies. The cooperation with Nuotai Biotech will enable it to quickly enter the first-class drug market with the help of the research and development results of GLP-1 drugs. The huge potential of this market will undoubtedly bring new growth opportunities to Boji Pharma.
Since its establishment in 2002, Boji Pharma has focused on providing a full range of services for the R&D and production of drugs, medical devices and health care products for domestic and foreign pharmaceutical companies. In 2015, the company was successfully listed on the Shenzhen Growth Enterprise Market (GEM), providing strong support for the innovation and development of the pharmaceutical industry through the "CRO+CDMO" model.
According to its 2023 semi-annual report, Boji Pharmaceutical's main business covers clinical research services, preclinical research services, other consulting services and other business income. Among them, clinical research services have become the main contributor to the company's revenue, accounting for 7482%。In addition, the company's performance in the first three quarters of 2023 was outstanding, achieving revenue of 358.8 billion yuan, a year-on-year increase of 2886%；The net profit attributable to the parent company reached 23.02 million yuan, a year-on-year increase of 756%。
However, looking back at the development of Boji Pharmaceutical, its performance has not been smooth sailing. Since its listing in 2015, the company has experienced ups and downs in performance. In 2015 and 2016, the company's revenue and net profit both declined, mainly due to the CFDA's self-inspection and verification of drug clinical trial data, which led to the slowdown in the progress of the company's clinical research trial projects. Despite this, since 2018, Boji Pharmaceutical's performance has gradually improved.
The cooperation with Nuotai Biotech will undoubtedly further consolidate Boji Pharmaceutical's market position in the field of diabetes. With the continuous expansion of the global diabetes market and the research and development of new first-class drugs, Boji Pharma is expected to achieve continuous growth in performance with its strong R&D strength and market layout.